相关临床试验
107
17 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2002
进行中（未招募）
17
15.9%
已完成
40
37.4%
招募中
14
13.1%
暂停
1
0.9%
终止
11
10.3%
Unknown
22
20.6%
撤回
2
1.9%
暂无批准数据
- NICE has recommended Enhertu for routine NHS use in England for adults with HER2-low advanced or metastatic breast cancer after prior treatment progression. - The decision follows a UK-US pharmaceutical pricing deal that raised NICE's cost-effectiveness threshold and a new quality-of-life assessment method. - Clinical trials showed Enhertu extended median overall survival to 23.4 months versus 16.8 months with standard chemotherapy, a 6.6-month gain. - About 1,000 patients a year in England are expected to be eligible, with Scotland already providing access since 2023 and 26 other European countries covering it.
- DNA sequencing of normal esophageal tissue from cancer patients shows chemotherapy and radiotherapy alter which mutant cell clones expand in healthy tissue. - Patients who received chemoradiotherapy (CROSS) had double the proportion of tissue carrying TP53 and PPM1D mutations compared with other treatment groups. - Combination chemotherapy increased normal cells carrying mutations linked to resistance to 5-fluorouracil, potentially protecting healthy tissue from toxicity. - Researchers found no chemotherapy-specific mutational signatures, suggesting most detected mutant clones pre-existed therapy and were selected rather than newly generated.
- A 25-year study of 22,534 UK adults found men with cardiovascular disease had a 17.3% lifetime cancer risk, compared with 12.8% for women with CVD. - Smoking, obesity and excessive alcohol consumption were identified as the primary drivers, with the strongest links seen in lung and oesophageal cancers. - Men with CVD also faced elevated mortality from gastric, oesophageal and lung cancers, prompting calls for improved risk management and targeted screening. - Researchers urged new care pathways to identify and prevent cancer in patients with cardiac conditions, reversing the current cardio-oncology focus.
- Adrian Webb, diagnosed in 2012 with advanced skin cancer that spread to his lungs, liver, spleen, bowel, lymph nodes and spine, was given just months to live. - After joining a clinical trial involving new immunotherapy drugs, scans showed his cancer regressing and later tests found no further trace of the disease. - Fourteen years after diagnosis, the 61-year-old is in remission and celebrating becoming a grandfather to six-month-old grandson Teddy. - Webb credits advances in research for his survival, noting around 34,600 people are diagnosed with cancer in the West Midlands each year.
- Cancer Research Horizons, the innovation arm of Cancer Research UK, has built a venture-capital-style model that recycles returns from drug-company exits back into research, with the $1.5 billion Myricx Bio acquisition by Novartis as its first seed-fund exit. - Only nine drugs won approval exclusively for children over the past 20 years, versus roughly 60 new adult cancer medicines approved in 2024 alone, which Cancer Research Horizons calls a market failure. - The See Further initiative, a roughly $50 million joint venture with LifeArc and Great Ormond Street Hospital Children's Charity, pursues a "child-first and child-only" strategy with two announced programs targeting Ewing sarcoma and multiple childhood cancers. - Charity capital can absorb higher risk and operate in commercially unattractive spaces, but the model remains unproven where it is most needed, with future fundraising dependent on a science-led portfolio across preclinical and clinical stages.
- Cancer Research UK has awarded a £2.5 million, five-year grant to fund the next phase of an ovarian cancer research programme led by Prof Stephen Taylor at The University of Manchester. - The laboratory houses the largest resource of living ovarian cancer cell cultures of its kind in the world, enabling researchers to identify new drug-targetable weaknesses. - The programme aims to develop better treatment options and move toward more personalised treatment for women with ovarian cancer. - Cancer survivor Gemma Coleman, who underwent surgical menopause at 34 after ovarian and womb cancer, welcomed the funding as a source of hope for future patients.
- AI-generated doctor accounts are spreading dubious health advice on TikTok, with AI content appearing in 40% of top health-related videos and averaging 2.5 million views per video. - The British Medical Association and NHS England have warned that misleading AI medical content poses a real threat to public health, with patients reporting increased worry and confusion. - Research found AI-generated doctors promoting disproven cancer myths and bizarre remedies including Coca-Cola mixed with onion as a pain-relief treatment. - Experts recommend examining health claims separately from the person making them, checking for supporting evidence, and being cautious about sweeping promises of rapid results.
- A 33-year-old UK mother was diagnosed with a rare gastrointestinal stromal tumour (GIST) after initially attributing her swollen stomach, night sweats, and fatigue to constipation. - GIST affects approximately 900 people annually in the UK and is most commonly diagnosed in those aged 55–65, making her diagnosis at age 31 particularly unusual. - Following surgery and imatinib treatment, her cancer returned aggressively, metastasized, and was deemed incurable and inoperable, leaving her on life-prolonging palliative care. - Her story was read in Parliament during discussions that led to the passage of the Rare Cancers Act this year, underscoring the need for greater symptom awareness.
- The Biomede trial, testing a US-approved drug combined with radiotherapy for DIPG, has been delayed in the UK due to post-Brexit regulatory divergence from the EU framework established in 2022. - Approximately 30 UK children are diagnosed annually with DIPG, an incurable brainstem tumour with a survival rate of "essentially zero," where most children die within two to three years of diagnosis. - Cancer Research UK reports that nine in 10 children's cancer doctors rely on international funding for trials, and the lack of UK-EU harmonisation has driven families to seek treatment overseas. - The MHRA says new regulations from April 2026 will strengthen alignment with international standards, but experts and charities urge immediate action to prevent treatment gaps.
- A new initiative called Island and Institutes partners Business Beats Cancer Guernsey with the universities of Southampton and Sussex to bring clinical research access to the island. - Blood cancer patients in Guernsey can now consent to have excess blood and tissue samples transported to the UK for use in ongoing clinical trials without needing to travel. - Lead oncologist Peter Gomes stated the program would be "very positive" in allowing patients to contribute to research that improves treatments for all. - Results will be shared with the local oncology team and could lead to more targeted treatments becoming available on the island.
